Literature DB >> 33468234

Cholestyramine treatment in two dogs with presumptive bile acid diarrhoea: a case report.

L Toresson1,2, J M Steiner3, J S Suchodolski3.   

Abstract

BACKGROUND: In people, bile acid diarrhoea is a prevalent complication of Crohn's disease and diarrhoea-associated irritable bowel syndrome. Affected patients typically respond to bile acid sequestrants, such as cholestyramine, but human gastroenterologists often fail to recognize bile acid diarrhoea. Consequently, bile acid diarrhoea is regarded as an underrecognized and undertreated condition in human medicine. Due to lack of diagnostic tools, clinical response to bile acid sequestrants is often used to confirm a diagnosis of bile acid diarrhoea in people. Several recent studies have shown that bile acid dysmetabolism also occurs in dogs with chronic enteropathies. It has further been shown that dogs with chronic enteropathies have significantly decreased expression of a bile acid transport protein in the ileum compared to healthy dogs, which correlates with faecal bile acid dysmetabolism. Consequently, in spite of the lack of reports in the literature, bile acid diarrhoea is likely to exist in dogs as well. CASE DESCRIPTIONS: Two dogs, an 8-year old Rottweiler and a 4.5-year old Siberian Husky were evaluated for chronic watery diarrhoea. Neither dog responded to dietary trials, probiotics, cyclosporine, faecal microbial transplantations or metronidazole. One of the dogs responded to high daily doses of corticosteroids, which were however associated with unacceptable side effects. The other dog was refractory to all standard treatment protocols, including cyclosporine and corticosteroids. Since none of the dogs responded satisfactorily to standard treatment or modulation of the intestinal microbiome, a suspicion of possible bile acid diarrhoea was raised. Treatment with cholestyramine, a bile acid sequestrant was initiated and resulted in marked improvement of faecal consistency, frequency of defecation and activity level in both dogs.
CONCLUSION: This report presents two dogs with presumed bile acid diarrhoea that were successfully treated with cholestyramine. Therefore, bile acid diarrhoea should be considered as a possible diagnosis in dogs with treatment-refractory chronic diarrhoea.

Entities:  

Keywords:  Bile acids; Cholestyramine; Diarrhoea; Dog

Year:  2021        PMID: 33468234      PMCID: PMC7814458          DOI: 10.1186/s40575-021-00099-x

Source DB:  PubMed          Journal:  Canine Med Genet        ISSN: 2662-9380


  5 in total

1.  [Hypoprothrombinemia and bleeding associated to treatment with cholestyramine (author's transl)].

Authors:  R Acuña; M González Ceron
Journal:  Rev Med Chil       Date:  1977-01       Impact factor: 0.553

2.  Vitamin K deficiency and bleeding after long-term use of cholestyramine.

Authors:  K Vroonhof; H J M van Rijn; J van Hattum
Journal:  Neth J Med       Date:  2003-01       Impact factor: 1.422

3.  Hypoprothrombinemic hemorrhage due to cholestyramine therapy.

Authors:  A M Shojania; D Grewar
Journal:  CMAJ       Date:  1986-03-15       Impact factor: 8.262

4.  Acceleration of the elimination of tenoxicam by cholestyramine in the dog.

Authors:  T W Guentert; M Schmitt; R Defoin
Journal:  J Pharmacol Exp Ther       Date:  1986-07       Impact factor: 4.030

5.  Fecal Microbial and Metabolic Profiles in Dogs With Acute Diarrhea Receiving Either Fecal Microbiota Transplantation or Oral Metronidazole.

Authors:  Jennifer Chaitman; Anna-Lena Ziese; Rachel Pilla; Yasushi Minamoto; Amanda B Blake; Blake C Guard; Anitah Isaiah; Jonathan A Lidbury; Jörg M Steiner; Stefan Unterer; Jan S Suchodolski
Journal:  Front Vet Sci       Date:  2020-04-16
  5 in total
  2 in total

1.  Correction to: Cholestyramine treatment in two dogs with presumptive bile acid diarrhoea: a case report.

Authors:  L Toresson; J M Steiner; J S Suchodolski
Journal:  Canine Med Genet       Date:  2021-05-20

Review 2.  Canine chronic enteropathy-Current state-of-the-art and emerging concepts.

Authors:  Albert E Jergens; Romy M Heilmann
Journal:  Front Vet Sci       Date:  2022-09-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.